(Q27691352)

title

PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development (English)

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

11

Birgit M Reipert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

15

Peter L Turecek

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Inge A Ivens

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

William Achanzar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Annamaria Brändli-Baiocco

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Joy Cavagnaro

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Maggie Dempster

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

B Olympe Depelchin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Armando R Irizarry Rovira

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Laura Dill-Morton

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Joan H Lane

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Theodora Salcedo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Becky Schweighardt

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Laurie S Tsuruda

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Jennifer Sims

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

October 2015

1 reference

published in

Toxicologic Pathology

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

43

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

7

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

959-983

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239651%20AND%20SRC:MED&resulttype=core&format=json

The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s)

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1177/0192623315591171

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

21 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Neutralizing antiviral B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Analytical measurement of PEGylated molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Pharmacokinetic consequences of pegylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

PEGylation of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

21 January 2018

Emerging PEGylated drugs

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Current challenges and opportunities in nonclinical safety testing of biologics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Development of the choroid plexus and blood-CSF barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

T cell-independent antigens type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Studies on tumor-promoting activity of polyethylene: inhibitory activity of metabolic cooperation on polyethylene surfaces is markedly decreased by surface modification with collagen but not with RGDS peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

New approaches to the management of hepatitis C in haemophilia in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Chemistry for peptide and protein PEGylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

The immunogenicity of polyethylene glycol: facts and fiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

The impact of PEGylation on biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

PEGylation, successful approach to drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

Development of a carbon-14 labeling approach to support disposition studies with a pegylated biologic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623315591171